Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kymera Therapeutics Inc
(NQ:
KYMR
)
48.36
+0.11 (+0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kymera Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
August 26, 2024
Via
Benzinga
Unveiling 6 Analyst Insights On Kymera Therapeutics
August 12, 2024
Via
Benzinga
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 07, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
July 31, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Why Kymera Therapeutics Stock Is Soaring Today
July 09, 2024
Kymera's lead pipeline candidate received some good news.
Via
The Motley Fool
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
June 17, 2024
Via
Benzinga
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
May 24, 2024
Via
Benzinga
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 09, 2024
Via
Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
July 09, 2024
Via
Benzinga
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
April 22, 2024
Via
Benzinga
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
February 23, 2024
Via
Benzinga
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
July 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
July 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 01, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
May 29, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 23, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
May 22, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
May 14, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
May 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 02, 2024
KYMR stock results show that Kymera Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
May 02, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
April 25, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
April 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
March 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
February 28, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
February 27, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.